| Literature DB >> 33789578 |
Galina Plotnikov1,2, Efraim Waizman1,2, Irma Tzur2,3, Alexander Yusupov2,3, Yonatan Shapira2,3, Oleg Gorelik4,5.
Abstract
BACKGROUND: Coronavirus disease 2019 (COVID-19) is a pandemic infection with substantial risk of death, especially in elderly persons. Information about the prognostic significance of functional status in older patients with COVID-19 is scarce.Entities:
Keywords: ADL; COVID-19; Elderly; Functional status; Hospitalization; Prognosis
Mesh:
Year: 2021 PMID: 33789578 PMCID: PMC8011046 DOI: 10.1186/s12877-021-02158-1
Source DB: PubMed Journal: BMC Geriatr ISSN: 1471-2318 Impact factor: 3.921
Characteristics of the patients included in the study, according to survival
| Variable | Entire group ( | Survivors ( | Non-survivors ( | * |
|---|---|---|---|---|
| Age (years) | 78.5±8.6 | 77.0±8.2 | 83.6±8.1 | |
| Male sex | 80 (43.0%) | 58 (40.6%) | 22 (51.2%) | 0.22 |
| Hypertension | 154 (82.8%) | 118 (83.7%) | 36 (82.5%) | 0.86 |
| Diabetes mellitus | 96 (51.6%) | 69 (51.7%) | 22 (51.2%) | 0.96 |
| Severe functional dependency | 89 (47.8%) | 33 (23.1%) | 21 (48.8%) | |
| Cerebrovascular disease | 86 (46.2%) | 61 (42.7%) | 25 (58.1%) | |
| Renal failure | 75 (40.3%) | 47 (32.9%) | 28 (65.1%) | |
Dementia Nursing-home residence | 74 (39.8%) 54 (29.0%) | 16 (14.3%) 33 (23.1%) | 27 (62.8%) 21 (48.8%) | |
| Heart failure | 42 (22.6%) | 25 (17.5%) | 17 (39.5%) | |
| Obesity | 40 (21.5%) | 29 (20.3%) | 11 (25.6%) | 0.46 |
| Coronary artery disease | 40 (21.5%) | 29 (20.3%) | 11 (25.6%) | 0.46 |
| Pessure sores | 32 (17.2%) | 20 (14.0%) | 12 (27.9%) | |
| Chronic lung disease | 30 (16.1%) | 23 (16.1%) | 7 (16.3%) | 0.97 |
| Malignant disease | 25 (13.4%) | 18 (12.6%) | 7 (16.3%) | 0.53 |
| Serum albumin on admission (normal 34-48 g/l) | 34.1±5.2 | 35.2±5.0 | 30.7±4.2 | |
| Serum CRP on admission (normal 0.3-5.0 mg/l) | 50.9 (17.2-123.0) | 40.0 (15.3-102.0) | 90.2 (43.8-171.5) | |
| Pneumonia during hospitalization | 120 (64.5%) | 83 (58.0%) | 37 (86.0%) | |
| Antibiotics | 133 (71.5%) | 93 (65.0%) | 40 (93.0%) | |
| Corticosteroids | 81 (43.5%) | 57 (39.9%) | 24 (55.8%) | 0.064 |
| Convalescent plasma | 40 (21.5%) | 30 (21.0%) | 10 (23.3%) | 0.75 |
| Tocilizumab | 39 (21.0%) | 30 (21.0%) | 9 (20.9%) | 0.99 |
| Remdesivir | 31 (16.7%) | 25 (17.5%) | 6 (14.0%) | 0.59 |
| Hydroxychloroquine | 27 (14.5%) | 18 (12.6%) | 9 (20.9%) | 0.17 |
| Oxygen via nasal canula/mask | 75 (40.3%) | 66 (46.2%) | 9 (20.9%) | |
| High flow oxygen | 17 (9.1%) | 6 (4.2%) | 11 (25.6%) | |
| Mechanical ventilation | 22 (11.8%) | 5 (3.5%) | 17 (39.4%) | |
| Admission to the intensive care unit | 34 (18.3%) | 12 (8.4%) | 22 (51.2%) | |
Data are presented as means ± standard deviations or medians (interquartile range) or numbers (percentages) of presented cases.
* Difference between survivors and non-survivors. CRP C-reactive protein. Bold entries in the table idicate a p-value of < 0.05.
Characteristics of the patients included in the study, according to age and functional dependency
| Variable | Group 1 (age 65-79 years without severe functional dependency, | Group 2 (age ≥80 years without severe functional dependency, | Group 3 (age 65-79 years with severe functional dependency, | Group 4 (age ≥80 years with severe functional dependency, | * |
|---|---|---|---|---|---|
| Age (years) | 71.1±3.8 | 83.7±2.8 | 73.2±4.1 | 87.9±5.3 | |
| Male sex | 37 (53.6%) | 7 (25.0%) | 18 (56.3%) | 18 (31.6%) | |
| Hypertension | 55 (79.9%) | 22 (78.6%) | 31 (96.9%) | 46 (80.7%) | 0.14b,d,f |
| Diabetes mellitus | 38 (55.1%) | 11 (39.3%) | 23 (71.9%) | 24 (42.1%) | |
| Cerebrovascular disease | 12 (17.4%) | 6 (21.4%) | 23 (71.9%) | 45 (78.9%) | |
| Renal failure | 16 (23.2%) | 15 (53.6%) | 14 (43.8%) | 30 (52.6%) | |
| Dementia | 2 (2.9%) | 1 (3.6%) | 23 (71.9%) | 48 (84.2%) | |
| Nursing-home residence | 1 (1.4%) | 2 (7.1%) | 18 (56.3%) | 33 (57.9%) | |
| Heart failure | 7 (10.1%) | 5 (17.9%) | 11 (34.4%) | 19 (33.3%) | |
| Obesity | 16 (23.2%) | 6 (21.4%) | 9 (28.1%) | 9 (15.8%) | 0.56 |
| Coronary artery disease | 16 (23.2%) | 5 (17.9%) | 8 (25.0%) | 11 (19.3%) | 0.87 |
| Pressure sores | 1 (1.4%) | 0 (0%) | 7 (21.9%) | 24 (42.1%) | |
| Chronic lung disease | 10 (14.5%) | 6 (21.4%) | 8 (25.0%) | 6 (10.0%) | 0.27 |
| Malignant disease | 3 (4.3%) | 3 (10.7%) | 8 (15.6%) | 14 (24.6%) | |
| Serum albumin on admission (normal 34-48 g/l) | 36.7±4.0 | 36.2±5.1 | 32.4±5.0 | 30.9±4.4 | |
| Serum CRP on admission (normal 0.3-5.0 mg/l) | 53.5 (17.7-123.7) | 34.9 (9.1-99.2) | 58.7 (18.4-136.6) | 52.6 (20.4-124.9) | 0.42 |
| Pneumonia during hospitalization | 42 (60.9%) | 17 (60.7%) | 23 (71.9%) | 38 (66.7%) | 0.69 |
| Antibiotics | 44 (63.8%) | 18 (64.3%) | 24 (75.0%) | 47 (82.5%) | 0.098c,e |
| Corticosteroids | 31 (44.9%) | 11 (39.3%) | 16 (50.0%) | 23 (40.4%) | 0.79 |
| Convalescent plasma | 27 (39.1%) | 7 (25.0%) | 4 (12.5%) | 2 (3.5%) | |
| Tocilizumab | 23 (33.3%) | 8 (28.6%) | 6 (18.8%) | 2 (3.5%) | |
| Remdesivir | 23 (33.3%) | 7 (25.0%) | 1 (3.1%) | 0 (0%) | |
| Hydroxychloroquine | 8 (11.6%) | 2 (7.1%) | 5 (15.6%) | 12 (21.1%) | 0.32 |
| Oxygen via nasal canula/mask | 31 (44.9%) | 8 (28.6%) | 7 (21.9%) | 29 (50.9%) | |
| High flow oxygen | 3 (4.3%) | 0 (0%) | 5 (15.6%) | 9 (15.8%) | 0.067d,e |
| Mechanical ventilation | 4 (5.8%) | 4 (14.3%) | 6 (18.8%) | 8 (14.0%) | 0.23b |
| Admission to the intensive care unit | 8 (11.6%) | 4 (14.3%) | 10 (31.3%) | 12 (21.1%) | 0.10b,d |
| Mortality | 6 (8.7%) | 5 (17.9%) | 6 (18.3%) | 26 (45.6%) | |
Data are presented as means ± standard deviations or medians (interquartile range) or numbers (percentages) of presented cases. CRP C-reactive protein. *Difference between all groups; aStatistically significant difference between groups 1 and 2; bStatistically significant difference between groups 1 and 3; cStatistically significant difference between groups 1 and 4; dStatistically significant difference between groups 2 and 3; eStatistically significant difference between groups 2 and 4; fStatistically significant difference between groups 3 and 4.
The variables that were most significantly associated with mortality in a multivariate logistic regression analysis
| Variable | Odds ratio | 95% confidence interval | |
|---|---|---|---|
| Group 1 (age 65−79 years, without severe functional dependency); the reference group | <0.001 | − | − |
| Group 2 (age ≥ 80 years, without severe functional dependency) | 0.20 | 2.63 | 0.60−11.42 |
| Group 3 (age 65−79 years, with severe functional dependency) | 0.58 | 1.46 | 0.38−5.59 |
| Group 4 (age ≥ 80 years, with severe functional dependency) | <0.001 | 10.42 | 3.27−33.24 |
| Pneumonia | 0.022 | 3.92 | 1.22−12.54 |
| Heart failure | 0.028 | 2.84 | 1.12−7.21 |
| Male sex | 0.057 | 2.37 | 0.98−5.76 |
| Serum C-reactive protein (for each 10 mg/l increment) | 0.026 | 1.06 | 1.01−1.11 |
| Renal failure | 0.074 | 2.20 | 0.93−5.22 |